论文部分内容阅读
目的分析Fibroscan测定联合血清学指标在检测肝硬化患者门静脉血流动力学指标中的应用价值。方法 40例肝硬化患者作为研究组,同期40例健康体检者作为对照组。比较两组Fibroscan值、血清学指标[透明质酸(HA)、Ⅳ型胶原(C-Ⅳ)、Ⅲ型前胶原(PCⅢ)]变化情况及门静脉血流动力学指标(门静脉内径、门静脉流速)变化情况。结果研究组Fibroscan值、HA、C-Ⅳ、PCⅢ均高于对照组,差异均有统计学意义(t=3.745、22.928、18.206、8.932,P<0.05)。研究组门静脉内径为(1.27±0.06)cm,门静脉流速为(14.46±1.95)cm/s;对照组门静脉内径为(1.15±0.05)cm,门静脉流速为(17.78±1.26)cm/s,研究组门静脉内径大于对照组,门静脉流速低于对照组,差异均有统计学意义(P<0.05)。结论 Fibroscan测定联合血清学指标可有效检测肝硬化患者门静脉血流动力学指标变化情况,具有推广价值。
Objective To analyze the value of Fibroscan combined with serological markers in the detection of portal vein hemodynamics in patients with cirrhosis. Methods Forty patients with cirrhosis as research group and 40 healthy subjects as control group. The changes of Fibroscan value, serological parameters [Hyaluronic acid (HA), type Ⅳ collagen (C-Ⅳ) and type Ⅲ procollagen (PCⅢ)] and portal vein hemodynamics Changes. Results The Fibroscan value, HA, C-Ⅳ and PCⅢ in the study group were significantly higher than those in the control group (t = 3.745,22.928,18.206,8.932, P <0.05). The diameter of the portal vein in the study group was (1.27 ± 0.06) cm and the portal vein velocity was (14.46 ± 1.95) cm / s in the study group. The portal vein diameter was (1.15 ± 0.05) cm in the control group and (17.78 ± 1.26) cm / The diameter of the portal vein was larger than that of the control group, and the velocity of the portal vein was lower than that of the control group (P <0.05). Conclusion Fibroscan combined with serum markers can effectively detect changes of portal vein hemodynamics in patients with cirrhosis, which has the promotion value.